Atogepant

Limits on what this shows

• Why no grade: Dual condition applied per Step 7: no Tier B/C mechanistic or class-level evidence connecting atogepant, or CGRP-receptor antagonism generally, to mitochondrial structure, membrane integrity, electron transport, or biogenesis was located, and no circulating consumer claim of mitochondrial harm from atogepant was identified to rebut as white. The oxidative-stress entry above (yellow, class-level, mAbs not atogepant) addresses systemic redox markers, not mitochondrial structure or biogenesis directly; the ATP production entry above (yellow, reverse-direction, mice only) addresses whole-body energy expenditure, not mitochondrial structure or biogenesis directly either, and its own source was directly fetched and confirmed this pass to contain no mitochondrial biogenesis, structure, or ATP-synthesis content. Neither was stretched to cover this separate, independently required category, per Hard Rule 7 and the prohibition against softening an absent mechanism into a possible one.

Channels tried this pass and outcome

Crossref API: a combined bibliographic query ("atogepant" plus "mitochondrial ATP copper iron") returned a genuine zero result (0 total-results, confirmed by direct inspection of the JSON response), the cleanest negative obtained this pass; a broader class-level query ("CGRP receptor antagonist gepant mitochondrial ATP energy metabolism") returned over 4 million loosely relevant results with none, among the top returned, addressing mitochondrial function specifically. PubMed search-listing page: one query succeeded (unlike the prior review's repeated 403s) but returned generic, non-CGRP mitochondrial biology papers (510,405 total results), indicating the query terms were not conjoined as intended by PubMed's parser rather than a true negative; a follow-up corrected-syntax query was rate-limited (HTTP 429) before it could run. Europe PMC REST API: HTTP 429 on every attempt this pass (an initial attempt returned HTTP 403, consistent with the organization-level policy denial recorded in the proxy status log at the start of this pass; later attempts in the same pass returned HTTP 429 instead, suggesting the block eased into ordinary rate-limiting as the pass progressed). OpenAlex Works API: HTTP 429 on every attempt this pass. Semantic Scholar Graph API: HTTP 429 on every attempt this pass. NCBI Bookshelf: the index page was reachable and confirmed a StatPearls chapter exists for atogepant, but two attempts to open the specific chapter both failed (one resolved to an unrelated StatPearls chapter via a tool mis-resolution, the second was rate-limited at HTTP 429 before the correct chapter could be confirmed open), so its content remains unverified rather than ruled out. Direct publisher pages (doi.org redirects to mdpi.com, nature.com) remained reachable throughout and were used successfully elsewhere in this pass (see Copper, Iron, and ATP production above), but no mitochondria-specific lead was in hand to follow to a publisher page for this category.

Assessment

This pass genuinely broadened the channel coverage (a clean Crossref zero-result, plus confirmation that the ATP production entry's own source contains no mitochondrial content) but did not fully resolve the NCBI Bookshelf StatPearls lead or complete a corrected-syntax PubMed query, both blocked by rate limiting mid-pass rather than returning content. This should be read as a genuine literature gap for atogepant specifically (a small molecule approved in 2021/2023 with limited drug-specific mechanistic literature beyond its CGRP-receptor pharmacology) compounded by a real, disclosed, partial tooling limitation on two specific leads, not as evidence of safety. A future revision should prioritize opening the atogepant StatPearls chapter (NCBI Bookshelf index confirms it exists) and re-running the corrected PubMed syntax query first.

Limits on what this shows

• Key negative/null findings: Two of three measured markers (FRAP, -SH) showed no significant change from baseline, explicitly reported by the study authors as a failure to replicate the antioxidant-capacity benefit seen with other migraine treatments in their broader research program. No placebo or untreated-comparator arm was included in this specific analysis.
• At-risk subgroups: None established; this is a single small cohort with no subgroup analysis reported.

Regulatory status

Not addressed in the current US label; no oxidative-stress biomarker language appears in the label.

Population evidence

De Luca C, Baldacci F, Mazzucchi S, Lombardo I, Curto L, Ulivi M, Chico L, Papa M, Siciliano G, Gori S. CGRP inhibitors and oxidative stress biomarkers in resistant migraine: a real-life study with erenumab, fremanezumab, and galcanezumab. J Clin Med. 2021;10(19):4586. Prospective, single-center study, University of Pisa Headache Centre, July 2020 to June 2021, n=42 resistant-migraine patients newly started on erenumab (n=23), galcanezumab (n=17), or fremanezumab (n=2). Advanced Oxidation Protein Products (AOPP), a marker of oxidative protein damage, fell significantly from a median of 291.4 to 236.2 nmol/L at 6 months (p=0.004). Ferric-Reducing Antioxidant Power (FRAP) showed no significant change (p=0.859); sulfhydryl/thiol groups (-SH) showed no significant change (p=0.110).

Mechanism

Proposed, not established at the molecular level: the authors suggest CGRP itself may carry antioxidant signaling properties, so pharmacologically blocking the CGRP pathway could theoretically blunt an antioxidant-capacity gain seen with other migraine treatments; this is a hypothesis offered to explain the study's own null findings on two of three markers, not a demonstrated mechanism.

Counter-evidence held on record

None of the three agents studied (erenumab, fremanezumab, galcanezumab) is atogepant or any gepant; this fails the cohort test for a drug-specific atogepant claim and is retained only as defensible class-level extrapolation because all three target the same CGRP signaling pathway atogepant also blocks, at the receptor (erenumab) or the ligand (fremanezumab, galcanezumab). Even within that class, results were mixed, with the majority of markers (2 of 3) showing no significant change, and no atogepant-specific redox data were located anywhere in this review. This is mechanistic/class-level evidence only, drawn from injectable CGRP-targeting antibodies with a different route of administration and a different direct molecular target than atogepant; it is not a basis for antioxidant supplementation in atogepant users, and no dosing recommendation follows from it.

Limits on what this shows

• Key negative/null findings: No atogepant registration-trial safety summary (the ADVANCE and PROGRESS phase 3 trials or their open-label extensions) reports a copper-related laboratory or adverse-event signal; the FDA label contains no copper-related monitoring parameter. A dedicated Crossref API query this pass ("atogepant" plus "copper" or "copper trace mineral") returned zero results.
• At-risk subgroups: Pre-existing lower plasma copper is reported in migraine patients broadly, independent of which, or whether any, preventive therapy they receive.

Regulatory status

Not addressed anywhere in the atogepant label; copper is not a named interaction or monitoring parameter.

Population evidence

Fila M, et al. 2023, Nutrients (DOI 10.3390/nu15020289), narrative review of nutrition and CGRP in migraine, directly refetched and re-verified this pass: the review states "women with migraine had lower plasma levels of Mg, Ca, Cu, and Zn than controls," citing its own reference 42, an underlying primary comparison of migraine patients versus controls. No CGRP-targeting drug, gepant, or monoclonal antibody is in the reviewed or underlying cohort; this is disease-epidemiology literature, not drug-safety literature, and does not pass the Step 4 cohort test above Tier C/D for atogepant specifically.

Mechanism

None specific to atogepant or to CGRP-receptor antagonism. The proposed disease-level mechanism concerns copper's role as a cofactor for antioxidant enzymes (e.g. superoxide dismutase, ceruloplasmin) and neurovascular function, unrelated to CGRP-receptor pharmacology.

Counter-evidence held on record

Confounding by indication is the default explanation here (Hard Rule 6): any lower copper observed in an atogepant-treated migraine population is, on current evidence, attributable to the underlying migraine population's baseline copper status, not to the drug. A dedicated drug-specific search this pass (Crossref API) returned a clean zero result for atogepant and copper. This is a population-context flag, not an atogepant-specific deficiency claim. Do not attribute a patient's copper status to atogepant therapy; evaluate it the same way it would be evaluated in any migraine patient, drug-treated or not.

Limits on what this shows

• Key negative/null findings: No atogepant registration-trial safety summary reports an iron-related laboratory or adverse-event signal. A dedicated Crossref API query this pass ("atogepant" plus "iron") returned zero results, a genuine negative, not a blocked attempt.
• At-risk subgroups: Migraine patients broadly, particularly those with other dietary risk factors for low iron intake, independent of preventive therapy.

Regulatory status

Not addressed anywhere in the atogepant label; iron is not a named interaction or monitoring parameter.

Population evidence

Fila M, et al. 2023, Nutrients (DOI 10.3390/nu15020289), the same review used under Copper, directly refetched and re-verified this pass: the review states migraine patients' "dietary intake of Mg, Cu, and Fe was lower than recommended," citing the same underlying reference 42. This is a self-reported dietary-intake finding, not a measured serum/plasma iron or ferritin deficit (the review's circulating-level statement covers Mg, Ca, Cu, and Zn, not Fe), so it is weaker than a true functional or circulating marker (Hard Rule 3) and is framed here strictly as an intake-level context flag. No CGRP-targeting drug is in the underlying cohort.

Mechanism

None specific to atogepant. Iron's proposed role in migraine pathophysiology concerns neurotransmitter synthesis and neurovascular function broadly, unconnected to CGRP-receptor pharmacology. A mechanistically adjacent lead, CGRP's role in macrophage polarization during bone/wound healing and the intestinal CGRP/macrophage axis (see Gut microbiome risk, yellow, above), does not extend to iron recycling, hepcidin, or ferroportin regulation in any source located this session, and was deliberately not stretched there.

Counter-evidence held on record

Confounding by indication is the default explanation (Hard Rule 6). The Crossref API returned a clean zero result for atogepant and iron this pass, consistent with no drug-specific literature existing yet, genuine gap rather than a tooling block for this particular query. This is a population dietary-intake context flag, not an atogepant-specific deficiency claim, and not a measured circulating deficit. Do not attribute a patient's iron status to atogepant therapy.

Limits on what this shows

• Key negative/null findings: This study measured intestinal inflammation, macrophage phenotype, and cytokine levels, not gut microbiome composition or diversity directly (no 16S sequencing or taxonomic analysis performed); its relevance to microbiome risk specifically, as opposed to mucosal immune regulation, is therefore indirect. The human arm is purely observational/correlational (endogenous CGRP tone in existing ulcerative colitis), not an interventional test of drug-induced CGRP blockade, and no gepant or CGRP monoclonal antibody was tested in either study arm.
• At-risk subgroups: None established in humans for a drug effect; patients with inflammatory bowel disease are a theoretical, unconfirmed subgroup of interest given the human correlational data.

Regulatory status

Not addressed in the current US label; no gastrointestinal-microbiome language appears in the label beyond the general GI adverse-effect profile (nausea, constipation) already covered in the Pharmacokinetic basis.

Population evidence

Wu W, Feng B, Liu J, Li Y, Liao Y, Wang S, Tao S, Hu S, He W, Shu Q, Liu Z, Yang P. The CGRP/macrophage axis signal facilitates inflammation recovery in the intestine. Clin Immunol. 2022;245:109154. Human arm: 30 ulcerative-colitis-in-remission patients versus 30 controls, colon biopsy, observational; lower endogenous CGRP correlated with higher inflammatory cytokines (TNF-alpha, IL-1beta, IFN-gamma) and CGRP positively correlated with TGF-beta. Animal arm: C57/B6 mice with dextran-sodium-sulfate-induced colitis; untreated colitis resolved spontaneously by day 15, while mice given a research anti-CGRP monoclonal antibody (not atogepant, not any approved migraine drug) showed prolonged weight loss and elevated inflammatory markers through day 30.

Mechanism

Named: CGRP induces TGF-beta-expressing CD4+ Tim4+ intestinal macrophages that suppress T-cell proliferation and promote inflammation resolution; experimental CGRP blockade removed this effect in mice.

Counter-evidence held on record

No approved CGRP-targeting drug, gepant or monoclonal antibody, was used in either study arm; the cohort test fails for atogepant specifically, and the finding is retained as mechanistic/class-level extrapolation only because it shares the same target pathway (CGRP signaling) that atogepant blocks. No human data link atogepant, or any approved CGRP inhibitor, to a measured change in gut microbiome composition. This is indirect, animal and observational evidence involving a research antibody, not atogepant or any approved gepant or monoclonal antibody; it is not a basis for probiotic, prebiotic, or microbiome-targeted supplementation in atogepant users.

Limits on what this shows

• Key negative/null findings: Neither hypertension nor Raynaud's phenomenon appears among the label's most-common (4 percent or greater, exceeding placebo) adverse reactions from controlled registration trials; both are drawn from the label's Warnings and Precautions and postmarketing-oriented language, and the FAERS case count is small (n=3) with a correspondingly wide confidence interval, consistent with an uncommon rather than a routine therapeutic-dose finding.
• At-risk subgroups: Patients with pre-existing Raynaud's phenomenon, peripheral vascular disease, or hypertension risk factors, per the label's cautionary framing; no quantified subgroup data located.

Regulatory status

Tier A. The current US label's Warnings and Precautions sections document new-onset or worsening hypertension, most frequently within 7 days of initiation and sometimes requiring discontinuation, and Raynaud's phenomenon, with symptom onset a median of 1.5 days following dosing in reported cases, often resulting in hospitalization, with resolution generally following discontinuation.

Population evidence

Lee N, et al. Disproportionality analysis of Raynaud's phenomenon associated with calcitonin gene-related peptide inhibitors using the FDA adverse event reporting system. Sci Rep. 2025;15:5675. FAERS cases of Raynaud's phenomenon across six CGRP inhibitors (erenumab, fremanezumab, galcanezumab, atogepant, rimegepant, ubrogepant) from each drug's approval date through August 2023: 89 of 186 total migraine-treatment-associated Raynaud's cases were linked to CGRP inhibitors as a class (class-wide reporting odds ratio 19.12, 95 percent CI 15.44 to 23.69). Atogepant-specific: 3 cases, 0.36 percent of all atogepant FAERS reports, reporting odds ratio 23.45 (95 percent CI 7.54 to 73.01).

Mechanism

Named. Alpha-CGRP is described in the cardiovascular-physiology literature as the most potent vasodilator identified to date, roughly 1,000 times more potent than acetylcholine, acting through cAMP/PKA signaling in vascular smooth muscle (Kumar et al., Front Physiol, 2022, background citation, atogepant not in cohort). Receptor blockade removes this compensatory vasodilatory tone; in an animal hypertension model, the CGRP-receptor antagonist CGRP8-37 (not atogepant) increased mean arterial pressure, consistent with loss of compensatory vasodilation as the operative mechanism class-wide.

Counter-evidence held on record

The large majority of atogepant-treated patients in registration trials did not develop hypertension or Raynaud's phenomenon; the FAERS signal is a spontaneous-reporting disproportionality measure (not an incidence rate) and does not establish individual-level causation, and n=3 is a small count carrying a wide confidence interval. This is a vascular/hemodynamic effect of atogepant's own intended CGRP-receptor engagement, not an iron, hemoglobin, or any other nutrient deficiency, and no supplement, diet change, or mineral repletion addresses it. New-onset limb color change, numbness, pain, or hypertension in a patient on atogepant should prompt contact with the prescriber, not nutrient supplementation.

Limits on what this shows

• Key negative/null findings: No human energy-metabolism, resting-metabolic-rate, or ATP-biomarker study in atogepant-treated patients was located this pass (Crossref API bibliographic query for atogepant plus "ATP energy metabolism" returned only pharmacokinetic mass-balance and molecular-dynamics studies of the drug molecule itself, not cellular energy metabolism). Atogepant's own labeled weight-loss signal is attributed to decreased appetite, not increased energy expenditure, and the two should not be read as confirming each other.
• At-risk subgroups: None established in humans.

Regulatory status

Not addressed in the atogepant label; not a recognized adverse-effect category. The label's own weight-loss signal (7 percent or more weight loss in 5.3 percent of patients at 60 mg versus 2.5 percent on placebo, already covered under Pharmacokinetic basis) is attributed there to decreased appetite, a changed-intake mechanism, and is not shown to share a mechanism with the rodent energy-expenditure finding below; the two are not conflated here.

Population evidence

Ramírez-Expósito et al. 2026, Int J Mol Sci 27(11):4973, DOI 10.3390/ijms27114973, narrative review of CGRP physiology, directly fetched and verified this pass. The review explicitly names atogepant as a second-generation gepant in its drug-class discussion, and separately reports, citing rodent studies: "endogenous CGRP contributes to high-fat-diet-induced weight gain by inhibiting sympathetic activity and reducing energy expenditure; its blockade improves insulin sensitivity and reduces adiposity in murine obesity models." Confirmed this pass that the blockade data is mechanism-agnostic in the review's own text (it does not distinguish small-molecule receptor antagonism from ligand-targeting antibodies when describing the rodent energy-expenditure effect), and the cohort is mice, not any human CGRP-pathway drug trial population, atogepant included. This is Tier C/B class-level mechanistic evidence under the cohort test, not atogepant-specific, and mirrors a yellow grade already assigned on this same source in this batch's fremanezumab dossier; it is extended here because the source itself names atogepant as a class member and the mechanism (loss of CGRP receptor signal transduction) is shared regardless of whether the blockade is receptor-targeted (atogepant) or ligand-targeted (the monoclonal antibodies).

Mechanism

Named at the rodent level only: intact endogenous CGRP tone is associated with reduced sympathetic activity and reduced energy expenditure; removing that tone (genetic or pharmacologic CGRP blockade) is associated with improved insulin sensitivity and reduced adiposity, i.e. a shift toward greater energy utilization, not an ATP-production deficit. No mitochondrial biogenesis, structure, or ATP-synthesis content appears anywhere in this source (confirmed this pass by direct fetch); it does not support the separate Mitochondrial burden category below.

Counter-evidence held on record

No human clinical confirmation exists in either direction; the rodent mechanism may not translate to atogepant or to humans. This entry rests on a single narrative review, not corroborated by any second independent source for atogepant specifically. Reverse-direction and purely theoretical; this is explicitly not a basis for any ATP-support or energy supplement recommendation, and is not evidence that atogepant's labeled weight-loss effect works through this mechanism.